此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Bispectral Index-Guided Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography (BIS-ERCP)

2026年11月1日 更新者:Ömer TÜRK、Van Training and Research Hospital

Effect of Bispectral Index (BIS) Monitoring on Postoperative Recovery Profile and Complications in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) Under Deep Sedation: A Randomized Controlled Trial

Endoscopic retrograde cholangiopancreatography (ERCP) requires deep sedation, and propofol is commonly used because of its rapid onset and recovery, but it has a narrow therapeutic window, especially in elderly patients. Bispectral index (BIS) monitoring provides an objective, electroencephalography (EEG)-based measure of sedation depth. This prospective, randomized, single-blind study compares BIS-guided titration of propofol infusion (target BIS 40-60) with standard clinical titration in elderly patients (65 years and older, American Society of Anesthesiologists (ASA) physical status III) undergoing ERCP, with respect to total anesthetic consumption, recovery time, hemodynamic and respiratory complications, and endoscopist satisfaction.

研究概览

详细说明

Patients aged 65 years and older, American Society of Anesthesiologists (ASA) physical status III, scheduled for endoscopic retrograde cholangiopancreatography (ERCP) under deep sedation will be randomized 1:1 using sealed envelopes to a bispectral index (BIS)-guided group or a standard care group. All patients receive standardized induction with intravenous (IV) midazolam 0.01 mg/kg, fentanyl 25 mcg and propofol 0.5 mg/kg, followed by a propofol infusion of 50-150 mcg/kg/min.

In the BIS group, the infusion rate is titrated to maintain BIS between 40 and 60, with additional low-dose propofol boluses when needed. In the standard group, BIS electrodes are attached and values are recorded blindly, but the monitor screen is hidden from the anesthesia team; the infusion rate is titrated according to heart rate, blood pressure, peripheral oxygen saturation (SpO2) and clinical signs (patient movement, gagging, swallowing).

ERCP is performed by a single experienced gastroenterologist blinded to group allocation. Heart rate, mean arterial pressure and SpO2 are recorded before and after induction, at 5, 10 and 15 minutes and at the end of the procedure. Recovery is assessed in the post-anesthesia care unit (PACU) using the Modified Aldrete Score.

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Van、土耳其(türkiye)
        • University of Health Sciences, Van Training and Research Hospital
        • 接触:
        • 首席研究员:
          • Ömer Türk, MD
        • 副研究员:
          • Sebat İldoğan, MD
        • 副研究员:
          • Cemal Kaçar, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 及以上 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 65 years or older
  • American Society of Anesthesiologists (ASA) physical status III
  • Scheduled for endoscopic retrograde cholangiopancreatography (ERCP) under sedation
  • Written informed consent obtained from the patient or legal guardian

Exclusion Criteria:

  • Refusal to participate or to sign the informed consent form
  • Known allergy or hypersensitivity to propofol, midazolam, fentanyl, or to egg or soy components
  • Advanced dementia, Alzheimer's disease, prior major cerebrovascular event (stroke), severe cognitive dysfunction or active neurological disease that may affect bispectral index (BIS) measurements
  • Local infection, wound, burn or anatomical deformity of the forehead preventing proper placement of BIS electrodes
  • ASA IV or higher, hemodynamic instability (shock) or need for active resuscitation before the procedure
  • Severe hearing or speech impairment or psychiatric disease preventing assessment with clinical recovery scales

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:BIS-Guided Sedation

Propofol infusion during ERCP is titrated to a target BIS of 40-60 using real-time bispectral index monitoring.

After standardized induction (midazolam 0.01 mg/kg, fentanyl 25 mcg, propofol 0.5 mg/kg IV), the propofol infusion (50-150 mcg/kg/min) is titrated according to real-time bispectral index (BIS) values to maintain a target BIS of 40-60, with additional low-dose propofol boluses when needed.

有源比较器:Standard Clinical Sedation

Propofol infusion during ERCP is titrated according to standard monitoring and clinical signs; BIS values are recorded but hidden from the anesthesia team.

After the same standardized induction, the propofol infusion (50-150 mcg/kg/min) is titrated according to standard monitoring (heart rate, blood pressure, SpO2) and clinical signs (movement, gagging, swallowing). BIS electrodes are attached and values are recorded, but the BIS screen is hidden from the anesthesia team.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Total Propofol Consumption
大体时间:From induction of sedation to the end of the ERCP procedure

Total amount of propofol (mg) administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure, including induction, infusion and additional boluses.

From induction of sedation to the end of the ERCP procedure

次要结果测量

结果测量
措施说明
大体时间
Gastroenterologist Satisfaction
大体时间:Immediately after the end of the ERCP procedure

Procedural comfort and satisfaction rated by the gastroenterologist, who is blinded to group allocation, on a 5-point Likert scale (1 = very poor, 5 = very good).

Immediately after the end of the ERCP procedure
Heart Rate
大体时间:Periprocedural: before induction, after induction, at 5, 10 and 15 minutes of the procedure, and at the end of the procedure

Heart rate (beats per minute) measured by standard electrocardiographic monitoring.

Periprocedural: before induction, after induction, at 5, 10 and 15 minutes of the procedure, and at the end of the procedure
Incidence of Sedation-Related Complications
大体时间:From induction of sedation to the end of the ERCP procedure

Number of participants with hypoxia (peripheral oxygen saturation, SpO2 < 90%), hypotension (mean arterial pressure < 65 mmHg or > 20% decrease from baseline) or bradycardia (heart rate < 50 beats per minute) during the procedure.

From induction of sedation to the end of the ERCP procedure
Number of Additional Propofol Boluses
大体时间:From induction of sedation to the end of the ERCP procedure

Number of additional propofol bolus doses given for signs of inadequate sedation (gagging, swallowing, patient movement) during the procedure.

From induction of sedation to the end of the ERCP procedure
Time to Discharge Readiness From the Post-Anesthesia Care Unit
大体时间:From the end of the procedure, up to 2 hours

Time (minutes) from the end of the procedure until the patient meets post-anesthesia care unit (PACU) discharge criteria according to the Modified Aldrete Score.

From the end of the procedure, up to 2 hours
Need for Airway Intervention
大体时间:From induction of sedation to the end of the ERCP procedure

Number of participants requiring any airway intervention during sedation, recorded by the highest level required: chin lift/jaw thrust, bag-mask ventilation, insertion of an oral/nasal airway or supraglottic device, or endotracheal intubation.

From induction of sedation to the end of the ERCP procedure
Mean Arterial Pressure
大体时间:Periprocedural: before induction, after induction, at 5, 10 and 15 minutes of the procedure, and at the end of the procedure

Mean arterial pressure (millimeters of mercury, mmHg) measured by non-invasive blood pressure monitoring.

Periprocedural: before induction, after induction, at 5, 10 and 15 minutes of the procedure, and at the end of the procedure
Peripheral Oxygen Saturation
大体时间:Periprocedural: before induction, after induction, at 5, 10 and 15 minutes of the procedure, and at the end of the procedure

Peripheral oxygen saturation (SpO2, percentage) measured by pulse oximetry.

Periprocedural: before induction, after induction, at 5, 10 and 15 minutes of the procedure, and at the end of the procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年4月1日

研究完成 (估计的)

2027年4月1日

研究注册日期

首次提交

2026年10月26日

首先提交符合 QC 标准的

2026年11月1日

首次发布 (实际的)

2026年11月6日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月1日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2026/07-01

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared publicly. De-identified data may be made available by the corresponding author upon reasonable request.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅